Total Liabilities Summary of D&D Pharmatech

D&D Pharmatech's latest annual total liabilities in 2023 was 23.98 Billion KRW , down -68.07% from previous year.
D&D Pharmatech's latest quarterly total liabilities in 2024 Q2 was 25.52 Billion KRW , up 146.22% from previous quarter.
D&D Pharmatech reported annual total liabilities of 75.12 Billion KRW in 2022, down -33.39% from previous year.
D&D Pharmatech reported annual total liabilities of 112.78 Billion KRW in 2021, up 135.67% from previous year.
D&D Pharmatech reported quarterly total liabilities of 25.52 Billion KRW for 2024 Q2, up 146.22% from previous quarter.
D&D Pharmatech reported quarterly total liabilities of -18.51 Billion KRW for 2023 Q1, down -124.65% from previous quarter.

Annual Total Liabilities Chart of D&D Pharmatech (2023 - 2019)

Name	Total Liabilities	Total Liabilities Difference
HLB Co., Ltd.	169.47 Billion KRW	85.847%
iNtRON Biotechnology, Inc.	1.88 Billion KRW	-1175.587%
BINEX Co., Ltd.	75.68 Billion KRW	68.309%
Bioneer Corporation	80.61 Billion KRW	70.245%
Anterogen.Co.,Ltd.	19.98 Billion KRW	-20.008%
MEDIPOST Co., Ltd.	135.73 Billion KRW	82.329%
CrystalGenomics, Inc.	97.82 Billion USD	75.48%
Helixmith Co., Ltd	73.55 Billion KRW	67.392%
Chabiotech Co.,Ltd.	1069.23 Billion KRW	97.757%
Medy-Tox Inc.	137.14 Billion KRW	82.51%
Peptron, Inc.	16.36 Billion KRW	-46.531%
Amicogen, Inc.	248.12 Billion KRW	90.333%
Genexine, Inc.	79.68 Billion KRW	69.899%
HLB Therapeutics Co.,Ltd.	29.27 Billion KRW	18.071%
LegoChem Biosciences, Inc.	41.28 Billion KRW	41.896%
ALTEOGEN Inc.	108.25 Billion KRW	77.844%
PharmaResearch Co., Ltd.	73.08 Billion KRW	67.182%
SillaJen, Inc.	19.4 Billion KRW	-23.631%
JETEMA, Co., Ltd.	179.09 Billion KRW	86.607%
OliX Pharmaceuticals,Inc	52.48 Billion KRW	54.304%
Genomictree Inc.	7.81 Billion KRW	-207.026%
MedPacto, Inc.	9.56 Billion KRW	-150.746%
EASY BIO,Inc.	105.86 Billion KRW	77.344%
GI Innovation, Inc.	9.63 Billion KRW	-148.912%